1921
Volume 101, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

In this study, we investigated the diagnostic utility of the cytokine profile of the cerebrospinal fluid (CSF) and enzyme-linked immunospot (ELISPOT) assays of patients with suspected tuberculous meningitis (TBM). We prospectively enrolled adult patients with suspected TBM, and CSF specimens were analyzed for 18 cytokines/chemokines and soluble programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1). Enzyme-linked immunospot assays were performed on mononuclear cells from the CSF (CSF-MCs) and peripheral blood (PBMCs). A total of 87 patients with meningitis, including 42 TBM-suspected patients and 45 non-TBM patients, were enrolled. Excluding the 32 patients with possible TBM, 10 patients with TBM and 45 patients with non-TBM were finally analyzed. Levels of adenosine deaminase (ADA), interleukin 12 subunit β (IL-12p40), IL-13, macrophage inflammatory protein α (MIP-1α), and soluble PD-1 and PD-L1 in the CSF were significantly higher in the TBM group than in the non-TBM group ( < 0.05). The optimal cutoff values for the sensitivities and specificities of the test methods for diagnosing TBM with small samples of 10 cases of definite or probable TBM were as follows: ADA > 6.95 U/L, 70% and 81%; IL-12p40 > 52.04 pg/mL, 80% and 73%; IL-13 > 0.44 pg/mL, 90% and 47%; MIP-1α > 8.83 pg/mL, 80% and 62%; soluble PD-1 > 35.87 pg/mL, 80% and 63%; soluble PD-L1 > 24.19 pg/mL, 80% and 61%; CSF-MC ELISPOT > 13.5 spots/250,000 CSF-MC, 30% and 91%; and PBMC ELISPOT > 14 spots/250,000 PBMCs, 50% and 78%, respectively. Therefore, CSF IL-12p40, IL-13, MIP-1α, and soluble PD-1 and PD-L1 concentrations appear to be useful adjuncts for diagnosing TBM.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0947
2019-07-01
2020-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/2/tpmd180947.html?itemId=/content/journals/10.4269/ajtmh.18-0947&mimeType=html&fmt=ahah

References

  1. WHO, 2017. Global Tuberculosis Report 2017. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  2. Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK, 2008. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 21: 243261.
    [Google Scholar]
  3. Thwaites GE, van Toorn R, Schoeman J, 2013. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol 12: 9991010.
    [Google Scholar]
  4. Torok ME, 2015. Tuberculous meningitis: advances in diagnosis and treatment. Br Med Bull 113: 117131.
    [Google Scholar]
  5. Ling DI, Flores LL, Riley LW, Pai M, 2008. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 2: e1536.
    [Google Scholar]
  6. Solomons RS, van Elsland SL, Visser DH, Hoek KG, Marais BJ, Schoeman JF, van Furth AM, 2014. Commercial nucleic acid amplification tests in tuberculous meningitis—a meta-analysis. Diagn Microbiol Infect Dis 78: 398403.
    [Google Scholar]
  7. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM Jr., 2003. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 3: 633643.
    [Google Scholar]
  8. Boehme CC et al., 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 10051015.
    [Google Scholar]
  9. Rufai SB, Singh A, Singh J, Kumar P, Sankar MM, Singh S, TB Research Team, 2017. Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. J Infect 75: 125131.
    [Google Scholar]
  10. Nhu NT et al., 2014. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. J Clin Microbiol 52: 226233.
    [Google Scholar]
  11. Bahr NC et al., 2018. Diagnostic accuracy of Xpert MTB/RIF ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis 18: 6875.
    [Google Scholar]
  12. Kim JY et al., 2018. Combined IFN-gamma and TNF-alpha release assay for differentiating active tuberculosis from latent tuberculosis infection. J Infect 77: 314320.
    [Google Scholar]
  13. Porsa E, Cheng L, Graviss EA, 2007. Comparison of an ESAT-6/CFP-10 peptide-based enzyme-linked immunospot assay to a tuberculin skin test for screening of a population at moderate risk of contracting tuberculosis. Clin Vaccine Immunol 14: 714719.
    [Google Scholar]
  14. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T, 2005. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 24: 529536.
    [Google Scholar]
  15. Wen A, Qu XH, Zhang KN, Leng EL, Ren Y, Wu XM, 2018. Evaluation of interferon-gamma release assays in extrasanguinous body fluids for diagnosing tuberculosis: a systematic review and meta-analysis. Life Sci 197: 140146.
    [Google Scholar]
  16. Huy NT, Thao NT, Diep DT, Kikuchi M, Zamora J, Hirayama K, 2010. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: a systemic review and meta-analysis. Crit Care 14: R240.
    [Google Scholar]
  17. Chen Z et al., 2012. The clinical diagnostic significance of cerebrospinal fluid D-lactate for bacterial meningitis. Clin Chim Acta 413: 15121515.
    [Google Scholar]
  18. Sharma S et al., 2017. Cytokines do play a role in pathogenesis of tuberculous meningitis: a prospective study from a tertiary care center in India. J Neurol Sci 379: 131136.
    [Google Scholar]
  19. Sakushima K, Hayashino Y, Kawaguchi T, Jackson JL, Fukuhara S, 2011. Diagnostic accuracy of cerebrospinal fluid lactate for differentiating bacterial meningitis from aseptic meningitis: a meta-analysis. J Infect 62: 255262.
    [Google Scholar]
  20. Kataria J, Rukmangadachar LA, Hariprasad G, O J, Tripathi M, Srinivasan A, 2011. Two dimensional difference gel electrophoresis analysis of cerebrospinal fluid in tuberculous meningitis patients. J Proteomics 74: 21942203.
    [Google Scholar]
  21. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, Eugen-Olsen J, Ravn P, Tbnet, 2008. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 32: 16071615.
    [Google Scholar]
  22. Demissie A, VACSEL Study Group et al., 2004. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol 172: 69386943.
    [Google Scholar]
  23. La Manna MP, Orlando V, Li Donni P, Sireci G, Di Carlo P, Cascio A, Dieli F, Caccamo N, 2018. Identification of plasma biomarkers for discrimination between tuberculosis infection/disease and pulmonary non tuberculosis disease. PLoS One 13: e0192664.
    [Google Scholar]
  24. Liu Y, Li X, Liu W, Liu Y, Zhong Z, Wang L, Ge S, Zhang J, Xia N, 2018. IL-6 release of Rv0183 antigen-stimulated whole blood is a potential biomarker for active tuberculosis patients. J Infect 76: 376382.
    [Google Scholar]
  25. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO, 2010. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a west African cohort. PLoS One 5: e12365.
    [Google Scholar]
  26. Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, Wherry EJ, 2014. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 40: 289302.
    [Google Scholar]
  27. Pauken KE, Wherry EJ, 2015. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36: 265276.
    [Google Scholar]
  28. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R, 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682687.
    [Google Scholar]
  29. Singh A, Mohan A, Dey AB, Mitra DK, 2013. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis 208: 603615.
    [Google Scholar]
  30. Yin W, Tong ZH, Cui A, Zhang JC, Ye ZJ, Yuan ML, Zhou Q, Shi HZ, 2014. PD-1/PD-Ls pathways between CD4(+) T cells and pleural mesothelial cells in human tuberculous pleurisy. Tuberculosis (Edinb) 94: 131139.
    [Google Scholar]
  31. Jurado JO, Alvarez IB, Pasquinelli V, Martinez GJ, Quiroga MF, Abbate E, Musella RM, Chuluyan HE, Garcia VE, 2008. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 181: 116125.
    [Google Scholar]
  32. McNab FW et al., 2011. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol 41: 19411947.
    [Google Scholar]
  33. Singh A, Mohan A, Dey AB, Mitra DK, 2017. Programmed death-1(+) T cells inhibit effector T cells at the pathological site of miliary tuberculosis. Clin Exp Immunol 187: 269283.
    [Google Scholar]
  34. Patel VB, Singh R, Connolly C, Kasprowicz V, Ndung’u T, Dheda K, 2011. Comparative utility of cytokine levels and quantitative RD-1-specific T cell responses for rapid immunodiagnosis of tuberculous meningitis. J Clin Microbiol 49: 39713976.
    [Google Scholar]
  35. Visser DH, Solomons RS, Ronacher K, van Well GT, Heymans MW, Walzl G, Chegou NN, Schoeman JF, van Furth AM, 2015. Host immune response to tuberculous meningitis. Clin Infect Dis 60: 177187.
    [Google Scholar]
  36. Yang Q et al., 2014. IP-10 and MIG are compartmentalized at the site of disease during pleural and meningeal tuberculosis and are decreased after antituberculosis treatment. Clin Vaccine Immunol 21: 16351644.
    [Google Scholar]
  37. Misra UK, Kalita J, Srivastava R, Nair PP, Mishra MK, Basu A, 2010. A study of cytokines in tuberculous meningitis: clinical and MRI correlation. Neurosci Lett 483: 610.
    [Google Scholar]
  38. Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, Donald PR, Wilkinson RJ, Marais BJ, 2010. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 10: 803812.
    [Google Scholar]
  39. Park KH et al., 2016. Diagnostic usefulness of T-cell based assays for tuberculous meningitis in HIV-uninfected patients. J Infect 72: 486497.
    [Google Scholar]
  40. Cooper AM, Solache A, Khader SA, 2007. Interleukin-12 and tuberculosis: an old story revisited. Curr Opin Immunol 19: 441447.
    [Google Scholar]
  41. Cooper AM, Kipnis A, Turner J, Magram J, Ferrante J, Orme IM, 2002. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol 168: 13221327.
    [Google Scholar]
  42. Holscher C, Atkinson RA, Arendse B, Brown N, Myburgh E, Alber G, Brombacher F, 2001. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 167: 69576966.
    [Google Scholar]
  43. Prando C et al., 2013. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) 92: 109122.
    [Google Scholar]
  44. Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ, 2006. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 177: 88448850.
    [Google Scholar]
  45. Cheng HY et al., 2014. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS One 9: e95870.
    [Google Scholar]
  46. Greisen SR, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, Horslev-Petersen K, Hvid M, Deleuran B, 2014. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol 43: 101108.
    [Google Scholar]
  47. Wei W, Xu B, Wang Y, Wu C, Jiang J, Wu C, 2018. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: a meta-analysis. Medicine (Baltimore) 97: e9617.
    [Google Scholar]
  48. Kruger S et al., 2017. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 6: e1310358.
    [Google Scholar]
  49. Pan X, Zhong A, Xing Y, Shi M, Qian B, Zhou T, Chen Y, Zhang X, 2016. Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion. Exp Ther Med 12: 21612168.
    [Google Scholar]
  50. Harari A et al., 2011. Dominant TNF-α+ Mycobacterium tuberculosis-speficific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 17: 372376.
    [Google Scholar]
  51. Jeong YH et al., 2015. Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production. J Clin Microbiol 53: 504510.
    [Google Scholar]
  52. Wang F, Hou H, Xu L, Jane M, Peng J, Lu Y, Zhu Y, Sun Z, 2013. Mycobacterium tuberculosis-specific TNF-α is a potential biomarker for the rapid diagnosis of active tuberculosis disease in Chinese population. PLoS One 8: e79431.
    [Google Scholar]
  53. Tobin DM et al., 2012. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148: 434446.
    [Google Scholar]
  54. Harishankar M, Selvaraj P, Bethunaickan R, 2018. Influence of genetic polymorphism towards pulmonary tuberculosis susceptibility. Front Med (Laussanne) 5: 213.
    [Google Scholar]
  55. Roca FJ, Ramakrishnan L, 2013. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 153: 521534.
    [Google Scholar]
  56. Bahr NC, Tugume L, Rajasingham R, Kiggundu R, Williams DA, Morawski B, Alland D, Meya DB, Rhein J, Boulware DR, 2015. Improved diagnostic sensitivity for tuberculous meningitis with Xpert(®) MTB/RIF of centrifuged CSF: a prospective study. Int J Tuberc Lung Dis 19: 12091215.
    [Google Scholar]
  57. Bonington A, Strang JI, Klapper PE, Hood SV, Rubombora W, Penny M, Willers R, Wilkins EG, 1998. Use of Roche AMPLICOR Mycobacterium tuberculosis PCR in early diagnosis of tuberculous meningitis. J Clin Microbiol 36: 12511254.
    [Google Scholar]
  58. Shirani K, Talaei Z, Yaran M, Ataei B, Mehrabi-Koushki A, Khorvash F, 2015. Diagnosed tuberculous meningitis using cerebrospinal fluid polymerase chain reaction in patients hospitalized with the diagnosis of meningitis in referral hospitals in Isfahan. J Res Med Sci 20: 224227.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0947
Loading
/content/journals/10.4269/ajtmh.18-0947
Loading

Data & Media loading...

Supplemental table and figure

  • Received : 27 Nov 2018
  • Accepted : 12 May 2019
  • Published online : 01 Jul 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error